RPG LifeScience.
RPG LifeScience. Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
What the Q4 FY26 call signalled
2 of 4 strong
The short version
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2% industry). Domestic formulation growth expected at ~12% annually, driven by volume expansion and new product launches, especially in cardiology, urology, and pain management. - API segment projected to grow 9-10% with a strong pipeline of 13 products and new market entries; Q4 FY26 showed a 144% bounce back in API revenues. - International formulation segment anticipated to return to growth following temporary inventory rationalization and regulatory improvements. - Volume-driven growth prioritized over price increases, with volumes growing 9.8% vs.
From RPG LifeScience.'s Q4 FY26 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2% industry).
- Focus on volume-backed growth rather than relying on price increases, especially as 30% of products fall under DPCO (Drug Price Control Order).
- New products in pipeline expected to launch with higher gross margins, enabling better price growth than previous years.
- International formulation segment poised for growth from FY27 onwards after temporary inventory rationalization, with expansion into new markets like Africa.
- API business seen as a significant medium-term growth driver, with 144% Q4 bounce back and a strong pipeline of 13 new products; consistent 9-10% growth expected.
2 more points from RPG LifeScience.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what RPG LifeScience. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- RPG Life Sciences has invested over INR 140 crores in capex over the last 4-5 years, focusing on modernizing and expanding facilities to drive cost efficiencies and position for future growth (Page 5).
- The company continues to invest in strengthening organizational capabilities and leadership pipeline via succession planning and capability-building initiatives (Page 6).
- Strategic focus is on both organic and inorganic growth, with the company actively looking for prudent, value-accretive inorganic opportunities in formulations and API business through M&A (Page 10).
2 more points from RPG LifeScience.'s call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
RPG LifeScience. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹177 Cr, net profit ₹30 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What RPG LifeScience.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pha. (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Arthneeti Pro · Annual
RPG LifeScience. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were RPG LifeScience. Q4 FY26 results?
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2% industry). Domestic formulation growth expected at ~12% annually, driven by volume expansion and new product launches, especially in cardiology, urology, and pain management. - API segment projected to grow 9-10% with a strong pipeline of 13 products and new market entries; Q4 FY26 showed a 144% bounce back in API revenues. - International formulation segment anticipated to return to growth following temporary inventory rationalization and regulatory improvements. - Volume-driven growth prioritized over price increases, with volumes growing 9.8% vs.
What is RPG LifeScience. share price analysis?
RPG LifeScience. currently shows a below-average growth signal. The stock trades at a P/E of 37.4 with a market cap of ₹4,361 Cr. Investors should review the full earnings analysis for detailed insights.
Is RPG LifeScience. planning capital expenditure?
RPG Life Sciences has invested over INR 140 crores in capex over the last 4-5 years, focusing on modernizing and expanding facilities to drive cost efficiencies and position for future growth (Page 5). - The company continues to invest in strengthening organizational capabilities and leadership pipeline via succession planning and capability-building initiatives (Page 6). - Strategic focus is on both organic and inorganic growth, with the company actively looking for prudent, value-accretive inorganic opportunities in formulations and API business through M&A (Page 10). - Investments include expansion into newer markets, increased R&D capabilities, and capacity building in both domestic and international formulations as well as API segments (Pages 4-5, 10). - The management emphasizes cautious approach towards investments like U.S.
Keep RPG LifeScience. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.